Samsung BioLogics Archives | Be Korea-savvy
Samsung Biologics Tentatively Agrees to Work with AstraZeneca on Contract Manufacturing

Samsung Biologics Tentatively Agrees to Work with AstraZeneca on Contract Manufacturing

SEOUL, Aug. 12 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday it has tentatively agreed to work with multinational pharmaceutical company AstraZeneca on biopharmaceutical contract manufacturing. The company said in a regulatory filing that it signed a letter of intent on the cooperation in a deal valued [...]

Samsung Biologics Establishes One-stop mRNA Vaccine Production Capability at Songdo Plant

Samsung Biologics Establishes One-stop mRNA Vaccine Production Capability at Songdo Plant

SEOUL, June 2 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding a mRNA vaccine substance production facility at its plant, a company official said Thursday. According to the official, Samsung has completed the addition [...]

Samsung Biologics, AstraZeneca Shutting Down Their Joint Venture Archigen Biotech

Samsung Biologics, AstraZeneca Shutting Down Their Joint Venture Archigen Biotech

SEOUL, May 24 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, is shutting down its joint venture with multinational pharmaceutical company AstraZeneca Plc., a company official said Tuesday, due to the suspension of the development of a biosimilar product. The move came two months after Samsung Biologics’ board approved [...]

Samsung Biologics Completes Acquisition of Biogen’s Entire Stake in Samsung Bioepis

Samsung Biologics Completes Acquisition of Biogen’s Entire Stake in Samsung Bioepis

SEOUL, April 20 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Wednesday it has completed the first payment to acquire the U.S. drugmaker’s entire stake in Samsung Bioepis. Earlier, Samsung Biologics reached a deal with Biogen to purchase the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 [...]

Samsung Biologics Eyes Global Market with Acquisition of Samsung Bioepis: CEO

Samsung Biologics Eyes Global Market with Acquisition of Samsung Bioepis: CEO

SEOUL, March 29 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, aims to expand its presence in the global market through full ownership of Samsung Bioepis, its chief executive said Tuesday. Samsung Biologics is the leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of [...]

Samsung Biologics to Acquire Biogen’s Entire Stake in Samsung Bioepis for US$2.3 bln

Samsung Biologics to Acquire Biogen’s Entire Stake in Samsung Bioepis for US$2.3 bln

SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday that it has reached a deal with Biogen Inc. to buy the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 billion. Currently, Biogen owns 50 percent minus one share in Samsung Bioepis, the joint venture [...]

Samsung Biologics to Manufacture AstraZeneca’s COVID-19 Antibody Combination

Samsung Biologics to Manufacture AstraZeneca’s COVID-19 Antibody Combination

SEOUL, Dec. 14 (Korea Bizwire) — British-Swedish pharmaceutical giant AstraZeneca said Tuesday that Samsung Biologics Co., the biotech arm of Samsung Group, will manufacture its antibody combination against COVID-19. Under an agreement valued at approximately US$380 million, Samsung Biologics will manufacture AZD7442 — AstraZeneca’s combination of two long-acting antibodies in development for the potential treatment [...]

Samsung Biologics Inks Manufacturing Deal with GreenLight

Samsung Biologics Inks Manufacturing Deal with GreenLight

SEOUL, Nov. 25 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. said Thursday it has signed a supply agreement with U.S.-based biotech company GreenLight Biosciences. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will manufacture drug substances for GreenLight’s mRNA COVID-19 vaccine candidate. Samsung Biologics will manufacture drug substances of the mRNA [...]